Jeffrey Gargano

Determining Venue For ANDAs Containing Paragraph IV Certification

Delaware Court Applies Acorda "Acts Of Infringement" Definition To Post-TC Heartland Venue Analysis

Unknown Problem Plus Nonobvious Solution Cannot Render Patent For Sublingual Formulation Of Asenapine Obvious

Supply and Purchase Agreement Triggers On-Sale Bar Provision of 35 USC § 102(b)

Hikma Successfully Moves To Dismiss Takeda's Induced Infringement Claims After Commercially Launching Its Mitigare® Drug For The Prevention Of Gout Flares

180-Day Notice Period For Biosimilar Approval Is Always Mandatory And Enforceable By Injunction

A No-AG Settlement Agreement Is Subject To Actavis' Rule Of Reason Analysis

Old Compound + Known Purpose + Prior Art Concentrations = Obvious